Acasti Pharma Research and Development Expenses 2014-2024 | GRCE

Acasti Pharma research and development expenses from 2014 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Acasti Pharma Annual Research and Development Expenses
(Millions of US $)
2024 $5
2023 $10
2022 $6
2021 $4
2020 $16
2019 $29
2018 $12
2017 $6
2016 $6
2015 $6
2015 $
2014 $4
2014 $
2013 $3
2013 $
Acasti Pharma Quarterly Research and Development Expenses
(Millions of US $)
2024-06-30 $3
2024-03-31 $2
2023-12-31 $1
2023-09-30 $0
2023-06-30 $1
2023-03-31 $2
2022-12-31 $2
2022-09-30 $3
2022-06-30 $3
2022-03-31 $2
2021-12-31 $2
2021-09-30 $1
2021-06-30 $0
2021-03-31 $0
2020-12-31 $1
2020-09-30 $1
2020-06-30 $2
2020-03-31 $2
2019-12-31 $4
2019-09-30 $4
2019-06-30 $6
2019-03-31 $8
2018-12-31 $7
2018-09-30 $7
2018-06-30 $7
2018-03-31 $5
2017-12-31 $3
2017-09-30 $3
2017-06-30 $1
2017-02-28 $1
2016-11-30 $1
2016-08-31 $1
2016-05-31 $2
2016-03-31
2016-02-29 $3
2015-12-31 $1
2015-09-30 $1
2015-06-30 $1
2015-03-31
2014-12-31 $2
2014-09-30 $2
2014-06-30 $1
2014-03-31
2014-02-28
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00